We have developed
blood cells, cMylc, for
research of COVID-19!
We have developed a human white blood cells, cMylc, based on Mylc cell optimized for the evaluation of the efficacy and safety of vaccines and drugs for COVID-19, which is shaking the world!
High precision and uniform blood cells produced using regenerative medicine technologies drastically accelerate the evaluation of the efficacy of drugs for COVID-19.
(Please contact us for details.)
MiCAN will exhibit our booth at the 5th Annual Meeting of the Japanese Society for Regenerative Medicine
We will present our seeds at the 5th Regenerative Medicine Industry-Academia Collaboration Techno-Auction.
Our company Miyazaki is scheduled to speak at the Blockbuster TOKYO Lifescience Startup career fair 2023.
Our research on antibody-dependent enhancement of infection using cMylc cells has been published in "Scientific Reports".
We are providing high precision immature blood cells developed for various types of evaluation of drugs and functional materials for cosmetics and foods, and offer a contract evaluation service using the blood cells.
High precision artificial blood cells
We can provide various types of uniform and high precision blood cells with identical genetic background, in any quantity you need, using iPS cell technology (regenerative medicine technology).
young red blood cells
Material for R&D for infectious diseases, etc. affecting red blood cells.
Immature dendritic cells
Material for evaluation of efficacy and safety
of drugs, etc.
Contract evaluation service
We also provide a contract evaluation service using our products for drugs and functional materials. You can select and design the blood cells. Our high precision and efficient evaluation can save you time and money.
functional materials, etc.
functional materials, etc.
(artificial dendritic cells produced using regenerative medicine technology)
changes the future of development of drugs and functional materials and research of infectious diseases!
Cell design capability
Cell design capability is our extraordinary core competence, unique to MiCAN.
We can design cells in a comprehensive manner based on various factors including selection of gene, control of differentiation stage,
and determination of the immortalization point.
Gene editing technology
We can produce blood cells reflecting various genetic backgrounds with genetic manipulation technology of progenitor cells.
We provide high-quality blood cells in a homogeneous differentiation
state from iPS cells with a high differentiation inducing rate.
Cell immortalization technology
We immortalize the cells just before each shipment. Thus, they maintain the original characteristics and can be used in experiments in a fresh condition.
Their characteristics are hard to change unlike originally
immortalized leukemia cell lines,
and you can obtain results similar to normal in vivo responses.
Consistent production technology
By improving the production efficiency, we can provide
the required number of blood cells stably at a reasonable price.